After 28 days, 22.5% of patients on Spravato attained remission versus 7.6% of patients in placebo. With MDD, remission is defined by a specified MADRS score. Because of the risk of dangerous ...

so patients can experience the efficacy of Spravato in as little as 24 hours, through day 28, without the need for a daily oral antidepressant." J&J said Spravato works by targeting glutamate ...

"Spravato is now available as a stand-alone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days -- without the need for daily oral ...

total score within 24 hours after the initial dose, with effects sustained for at least four weeks. Spravato’s safety profile aligns with existing data for oral antidepressants, with no new ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for J&J but only as an adjunct therapy to oral antidepressants for TRD.

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, multicenter, placebo-controlled trial. On day 28 of the trial, patients taking ...